Cidara Therapeutics
Cidara Therapeutics develops targeted immunotherapies using its proprietary Cloudbreak platform, aiming to improve care for patients with serious diseases. Headquartered in San Diego, the company is advancing treatments for influenza, cancer, and autoimmune diseases.
About Cidara Therapeutics
Cidara Therapeutics is a biotechnology company specializing in the development of targeted immunotherapies aimed at saving lives and enhancing patient care. Headquartered in San Diego, California, Cidara focuses on innovative therapies for serious diseases. The company leverages cutting-edge technology to design treatments that inhibit disease targets and engage the immune system.
Cloudbreak Platform
Cidara Therapeutics employs its proprietary Cloudbreak platform to create novel drug-Fc conjugates (DFCs). This platform merges targeted small molecules and peptides with human antibody fragments (Fc) to form 'single molecule cocktails.' These DFCs are crafted to both inhibit specific disease targets and activate the immune system, presenting a dual-function approach to treatment.
CD388 for Influenza Prevention
Cidara's CD388 is a promising drug-Fc conjugate currently in Phase 2 clinical trials. Designed for the universal prevention of both seasonal and pandemic influenza, CD388 aims to offer protection against influenza A and B with a single dose. This innovative approach could significantly simplify influenza prevention and enhance its effectiveness.
Research and Development Programs
Apart from influenza, Cidara Therapeutics is also advancing multiple preclinical and discovery programs. These initiatives target cancer and autoimmune diseases, areas with urgent unmet medical needs. By focusing on these critical conditions, Cidara aims to expand the impact of its proprietary platform and develop breakthrough therapies.